What insurance policy changes affect code D68.022?

There are 3 tracked policy changes affecting code D68.022, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D68.022?

Payers that have issued tracked updates for code D68.022 include: Aetna.

How do I get notified when code D68.022 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D68.022. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D68.022?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

D68.022 Insurance Policy Changes

ICD-10 D68.022 is officially defined as "Von Willebrand disease, type 2M." code D68.022 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D68.022 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 15, 2026Medium impact
Autoimmune Antibody and Coagulation Testing (CPB 0662, reviewed 2026-10-14)
Aetna considers the PF4-dependent P-selectin expression assay (PEA) for members with suspected heparin-induced thrombocytopenia who need additional testing, and several von Willebrand factor assays, medically necessary when criteria are met. Those assays include VWF collagen binding for suspected type 2A, 2B or 2M von Willebrand disease, VWF factor VIII binding for suspected type 2N, and VWF multimer analysis with ristocetin-induced platelet aggregation to determine the type in diagnosed members. Antiprothrombin antibody testing, detection of elevated factor VIII and VWF levels for acute ischemic stroke risk, and VWFpp/VWF:Ag for type 1C von Willebrand disease are considered experimental, investigational or unproven because their clinical value has not been established.
Aetna · Identified Aug 13, 2026Medium impact
Clotting Factors (CPB 0131, reviewed 2026-04-23)
Aetna's clotting factor policy applies to commercial medical plans, and the Medicare criteria are set out separately in the Medicare Part B Criteria. Precertification of clotting factors is required of all Aetna participating providers and members in applicable plan designs, and it is requested through Aetna's Special Case Precertification Unit at (855) 888-9046. Clotting factor products must be prescribed by or in consultation with a hematologist, and Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Autoimmune Antibody and Coagulation Testing (CPB 0662, reviewed 2025-12-08)
Aetna considers these coagulation tests medically necessary when criteria are met: the PF4-dependent P-selectin expression assay as a confirmatory functional assay for members with suspected heparin-induced thrombocytopenia who require additional diagnostic testing; von Willebrand factor collagen binding assays to diagnose type 2A, 2B or 2M von Willebrand disease in members suspected of those types who need additional testing; the von Willebrand factor factor VIII binding assay to diagnose type 2N VWD in members suspected of type 2N who need additional testing; and von Willebrand factor multimer analysis and ristocetin-induced platelet aggregation to determine VWD type in members diagnosed with VWD. Antiprothrombin antibody testing, detection of elevated factor VIII and VWF levels for assessment of acute ischemic stroke risk, and the von Willebrand factor propeptide antigen assay for VWD type 1C are considered experimental, investigational or unproven.

Watch D68.022

Get one email when a payer policy names D68.022, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Autoimmune Antibody and Coagulation Testing (CPB 0662, reviewed 2026-10-14)

Clotting Factors (CPB 0131, reviewed 2026-04-23)

Autoimmune Antibody and Coagulation Testing (CPB 0662, reviewed 2025-12-08)

What insurance policy changes affect code D68.022?

Which payers have updated policy for code D68.022?

How do I get notified when code D68.022 policy changes?

Why do payers change policies for code D68.022?